Moleculin Biotech to Present at Upcoming Cancer Research Meeting
HOUSTON, Texas -- Moleculin Biotech, Inc. (Nasdaq: MBRX), a clinical-stage pharmaceutical company, has exciting news regarding its abstract presentation slated for the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled to take place from April 25-30, 2025, at the McCormick Place Convention Center in Chicago.
Details of the AACR Presentation
The abstract will highlight the company’s promising next-generation anthracycline, Annamycin. This achievement underscores Moleculin's commitment to developing therapies for challenging cancers and viral infections.
Presentation Title and Track
The presentation, titled Combining Annamycin, a Non-cardiotoxic Potent Topo II Poison, with Azacitidine, Cytarabine, Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to Synergize Anticancer Effects and Identify Potential Clinical Applications, focuses on novel drug combination strategies for effective cancer treatment. The session aims to explore innovative solutions for improving outcomes in oncology.
Session and Presenter Information
The abstract can be found in the Experimental and Molecular Therapeutics track, specifically under the session for Drug Combination Strategies for Cancer Treatment. Rafal Zielinski, Ph.D., from the Department of Experimental Therapeutics at MD Anderson Cancer Center, will lead the session, presenting from 9:00 AM to 12:00 PM ET on April 28, 2025, at Section 19.
About Moleculin Biotech
Moleculin Biotech is at the forefront of innovation in treating hard-to-treat tumors and certain viral infections. One of its most notable developments is Annamycin, which is designed to minimize the harmful cardiotoxic effects frequently associated with standard anthracycline treatments while effectively combating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
In an exciting expansion of its research, the company plans to initiate the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive Phase 3 trial that evaluates Annamycin when combined with cytarabine, collectively known as AnnAraC. Moleculin's efforts have gained momentum after a successful Phase 1B/2 study (MB-106), and with positive feedback from regulatory authorities, the company feels confident about navigating forward to a potential approval pathway for Annamycin.
Moreover, Moleculin is pioneering new treatments such as WP1066, an Immune/Transcription Modulator that works to inhibit oncogenic transcription factors while enhancing the body's immune response against challenging cancers including brain tumors and pancreatic cancers. The company is also pioneering a line of antimetabolites like WP1122, geared towards addressing pathogenic viruses as well as some cancers.
Company Connections
For those interested in learning more about Moleculin’s submissions and clinical trials, the company encourages you to visit their official website. Staying connected is vital for future updates regarding their operations and breakthroughs in cancer treatment.
Contact Information
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
Frequently Asked Questions
What is the primary focus of the presentation at the AACR Annual Meeting?
The focus is on the potential of Annamycin in combination with other drugs to enhance anticancer effects.
Who is the presenter of the abstract?
Rafal Zielinski, Ph.D., from MD Anderson Cancer Center will present the abstract.
What is Annamycin?
Annamycin is a next-generation anthracycline designed to treat certain forms of leukemia and reduce cardiotoxicity.
When is the AACR Annual Meeting taking place?
The AACR Annual Meeting will occur from April 25-30, 2025.
How can I find out more about Moleculin's projects?
You can visit their official website for the latest updates on their projects and research activities.
